SCHEMBL1304322

SCHEMBL1304322

O=C1Nc2ccc(C(=O)[O-])cc2/C1=C\c1ccc(/C=C2/C(=O)Nc3ccc(C(=O)[O-])cc32)o1.[Na+].[Na+]

nearest known ligand 0.52

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
THRB known ✓ P10828 1/20 0.47
RET P07949 4/20 0.52
TLK2 Q86UE8 9/20 0.48
PDPK1 O15530 2/20 0.48
JAK3 P52333 2/20 0.48
PIM1 P11309 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
DYRK1A Q13627 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
ALOX12 P18054 1/20 0.47
CDK1 P06493 1/20 0.45
CCNB1 P14635 1/20 0.45
NEK2 P51955 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141668 0.86 TLK2 (0.63) RETTLK2PDPK1JAK3PIM1
SCHEMBL3141680 0.86 TLK2 (0.63) RETTLK2PDPK1JAK3PIM1
SCHEMBL1304319 0.85 TLK2 (0.62) RETTLK2PDPK1JAK3PIM1
SCHEMBL1304323 0.85 TLK2 (0.62) RETTLK2PDPK1JAK3PIM1
SCHEMBL1304353 0.83 PTPN1 (0.46) RETTLK2PIM1MEN1KMT2A
SCHEMBL12111136 0.77 TLK2 (0.52) RETTLK2PDPK1JAK3PIM1
SCHEMBL1304859 0.74 ALDH1A1 (0.43) PIM1MEN1KMT2ADYRK1AALDH1A1
SCHEMBL1305323 0.72 POLB (0.80) RETTLK2PDPK1JAK3PIM1
SCHEMBL1305325 0.72 POLB (0.80) RETTLK2PDPK1JAK3PIM1
SCHEMBL3130088 0.71 PIM1 (0.52) TLK2PDPK1JAK3PIM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053461-B2 Oxindole derivative THERAVALUES CORPORATION (JP) 2011-11-08 US disclosed
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE THERAVALUES CORPORATION (JP) 2010-03-25 US disclosed
EP-2130829-A1 NOVEL HYDROXYINDOLE DERIVATIVE Theravalues Corporation (JP) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE CYP2C9, HDAC10, SIGMAR1 THRB 2003/4885RET 859/4885TLK2 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.